A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335
Status:
Completed
Trial end date:
2017-08-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of a single oral dose of
AL-335 in participants with various degrees of impaired renal function (mild, moderate, and
severe) compared to participants with normal renal function.